AlloVir (AlloVir) Accumulated other comprehensive income (loss) : $-0.14 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is AlloVir Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. AlloVir's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was $-0.14 Mil.

AlloVir's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2023 ($-0.20 Mil) to Dec. 2023 ($-0.06 Mil) but then declined from Dec. 2023 ($-0.06 Mil) to Mar. 2024 ($-0.14 Mil).

AlloVir's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 ($-0.16 Mil) to Dec. 2022 ($-0.47 Mil) but then increased from Dec. 2022 ($-0.47 Mil) to Dec. 2023 ($-0.06 Mil).

AlloVir Accumulated other comprehensive income (loss) Historical Data

The historical data trend for AlloVir's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlloVir Accumulated other comprehensive income (loss) Chart

AlloVir Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

0.07

-0.11

-0.16

-0.47

-0.06

AlloVir Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															-0.30	-0.23	-0.20	-0.06	-0.14

AlloVir Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

AlloVir Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of AlloVir's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

AlloVir (AlloVir) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlloVir Inc (NAS:ALVR) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1100 Winter Street, Waltham, MA, USA, 02451

Website

https://www.allovir.com

AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.

Executives

Vikas Sinha	director, 10 percent owner, officer: See Remarks	C/O ALEXION PHARMACUETICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Diana Brainard	director	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Edward Miller	officer: General Counsel	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Brett R Hagen	officer: Chief Accounting Officer	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Cintia Piccina	officer: Chief Commercial Officer	60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Derek N. Adams	director	ALLOVIR, INC., 1100 WINTER STREET, WALTHAM MA 02451
Van Beek Jeroen B	officer: Chief Commercial Officer	C/O TRICIDA, INC., 7000 SHORELINE COURT, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Ercem Atillasoy	officer: See Remarks	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
David Hallal	director, 10 percent owner, officer: Chief Executive Officer	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
F2 - Tpo Investments Llc	director, 10 percent owner	C/O SINGER, MCKEON INC., 8 W 38TH ST SUITE 1001, NEW YORK NY 10018
F2 Bioscience Av 2022 Llc	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Capital I 2020 F2	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
F2 Mc, Llc	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Globeways Holdings Ii Ltd	director, 10 percent owner	C/O SINGER, MCKEON INC., 8 W 38TH ST. STE. 1001, NEW YORK NY 10018